Friday, June 19, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “sacituzumab tirumotecan” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 8
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 8 pipeline programs matching "sacituzumab tirumotecan" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

8 results for “sacituzumab tirumotecan” Back to intelligence hub

Search results

  1. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Breast Neoplasms

    phase 3 small molecule active

    1 trial
  2. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non Small Cell Lung Cancer

    phase 3 mab active

    1 trial
  3. Sacituzumab tirumotecan

    Merck KGaA, Darmstadt, Germany

    Non-small Cell Lung Cancer (NSCLC)

    phase 3 mab active

    2 trials
  4. Sacituzumab Tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Extensive-Stage Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  5. Sacituzumab Tirumotecan and Limertinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    EGFR-mutant Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  6. Sacituzumab Tirumotecan in combination with tislelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial
  7. Sacituzumab tirumotecan

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    TNBC - Triple-Negative Breast Cancer

    phase 2 small molecule active

    1 trial
  8. Trilaciclib and Sacituzumab Tirumotecan

    The First People's Hospital of Lianyungang

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.